Section Meeting – January 8th, 2013
I. Presentation overview—Lynn Tang, PhD, Associate Professor, College of New Jersey
China’s 12th Five Year Plan (2011-2015) offers an important framework for China’s economic and social development. It is also a significant document for China’s partners in the world economy because it presents both opportunities to do business with China and challenges to compete with Chinese companies in the global marketplace. Policy makers should also heed to China’s call for accomplishing the Plan’s goals.
The presentation briefly describes the nature of the Plan and explains the implications of the Plan to US businesses. Emphasis is placed on opportunities in China for companies in the health, technology and environmental sectors over the next 5-10 years.
The presenter will encourage wide audience participation. Several simple questions will be posed to the audience at the beginning of the presentation to engage them in discussion. Participants will benefit from the presentation by learning about the planned direction of the Chinese economy over the next few years, the implications of China’s policies for domestic and international business, and the role that U.S. businesses can play in this new economic environment.
II. Presentation Overview—Irene Wei, PhD, CQA, CEO, CSR Pharma Services, Inc
Since 2001, when China entered the World Trade Organization, to today when China has hosted the Summer Olympics in 2008 and the World Expo in 2010, the country has evolved into the global low-cost Manufacturing powerhouse with a sizeable sovereign wealth of about USD $3 trillion. Beginning a new decade, we see a changing Healthcare and Life Sciences landscape in the 21st Century with China developing and becoming a new Global Epicenter for Life Sciences Research and Innovation. The U.S. may still be the world’s superpower, but China and India are rapidly vying for world dominance in Biopharma by adding more research and innovation to their life sciences industry. There is a growing competition among these three nations for biopharma enterprises and their jobs, as they all look to this industry (pharmaceutical and biotech) for future growth.
The presentation will briefly describe the current market landscape in China and summarize the implications of Quality to US health, technology and environment businesses. Emphasis will be placed on new regulations that may have relevance to other industries. The presenter will discuss challenges and opportunities in China for U.S. companies in this decade.
Lynn Tang, PhD, is an Associate Professor of International Business at the College New Jersey. She received her Ph.D. in international economics from Syracuse University. Her publications appear in top academic journals such as Energy Economics, International Business Review, Journal of International Business Studies, Review of International Economics, and etc. She has been frequently interviewed by the media and her comments were quoted in China related articles by Business Insider, Yahoo Finance, and International Business Times. Dr. Tang is the project director of the 2010-2012 Business and International Education grant awarded by U.S. Department of Education. Through the grant, she led two business tours of China in 2011 and 2012, organized the first International Business Symposium on Doing Business with China at TCNJ, and helped New Jersey and Pennsylvania companies to enter Chinese market.
Irene Wei, PhD, MBA, is an ASQ Certified Quality Auditor (CQA) and has over 25 years of experience in the FDA-regulated pharmaceutical, biotech and food industries. As a management and scientific executive professional, she has been involved with the successful product development and commercialization of chemical and biotech drug products, medical devices and diagnostics, and clinical nutritional products from Big Pharma companies, biotech companies and specialty Pharma companies, including Baxter, Immunomedics and Merck. She is Founder and CEO of CSR Pharma Services, Inc., which provides market expansion services and IT software products in Product Development and Commercialization of FDA-regulated healthcare products to enhance productivity, cost and resource efficiency, and research innovation. She received her MBA from Rutgers University, doctoral degree in life sciences from M.I.T. and health research experience from the National Institutes of Health (N.I.H.).
TIME & PLACE:
Date: January 8, 2013,
Location: Spanish Tavern, 103 McWhorter Street – Newark, NJ 07105
Duration: 6:00pm to 8:30pm
Free for ASQ NY/NJ Metropolitan Section 0300 members with registration
Contact the registrar at email@example.com or follow this link for registration in December 2012: http://asqmetro0113.eventbrite.com/